Article
Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2014
Blatt Katharina, Herrmann Harald, Hoermann Gregor, Willmann Michael, Cerny-Reiterer Sabine, Sadovnik Irina, Herndlhofer Susanne, Streubel Berthold, Rabitsch Werner, Sperr Wolfgang R, Mayerhofer Matthias, Rülicke Thomas, Valent Peter
Abstract excerpt
PURPOSE: The CD52-targeted antibody alemtuzumab induces major clinical responses in a group of patients with myelodysplastic syndromes (MDS). The mechanism underlying this drug effect remains unknown. EXPERIMENTAL DESIGN: We asked whether neoplastic stem cells (NSC) in patients with MDS (n = 29) or acute myelogenous leukemia (AML; n = 62) express CD52. RESULTS: As assessed by flow cytometry, CD52 was found to be...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.